Abstract
One of the most common melanoma-related CDKN2A mutations reported in North America is the V126D mutation. We examined nine markers surrounding CDKN2A in three American and four Canadian families carrying the V126D mutation. All seven families had a haplotype consistent with a common ancestor/founder for this mutation. In addition, the mutation appears to have originated 34–52 generations ago (1-LOD-unit support interval 13–98 generations). © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Borg A, Johansson U, Johansson O, Hakansson S, Westerdahl J, Masback A, Olsson H and Ingvar C (1996) Novel germline p16 mutation in familial melanoma in southern Sweden. Cancer Res 56: 2497–2500
Chin L, Merlino G and DePinho RA (1998) Malignant melanoma: modern black plague and genetic black box. Genes Dev 12: 3467–3481
Ciotti P, Struewing JP, Mantelli M, Chompret A, Avril M-F, Santi PL, Tucker MA, Bianchi-Scarra G, Bressac-de Paillerets B and Goldstein AM (2000) A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 67: 311–319
Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainero ML, Ferrari C, Santi PL, De Marchi R, Farris A, Ajmar F, Bruzzi P and Bianchi-Scarra G (1999) Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 12: 441–448
Goldstein AM, Struewing JP, Chidambaram A, Fraser MC and Tucker MA (2000) Genotype-phenotype relationships in American melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 92: 1006–1010
Goldstein AM and Tucker MA (2001) Familial melanoma and its management. Genetic Predisposition to Cancer Eeles R, Easton D, Eng C and Ponder B (eds) Arnold: London
Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W and Frants RR (1995) Homozygotes for CDKN2A (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 10: 351–353
Hashemi J, Bendahl P-O, Sandberg T, Platz A, Linder S, Stierner U, Olsson H, Ingvar C, Hansson J and Borg Å (2001) Haplotype analysis and age estimation of the 113 insArg CDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes Cancer
Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark Jr WH, Tucker MA and Dracopoli NC (1994) Germline p16 mutations in familial melanoma. Nature Genet 8: 15–21
Kefford RF, Newton Bishop JA, Bergman W and Tucker MA (1999) Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 17: 3245–3251
Liu L, Dilworth D, Gao L, Monzon J, Summers A, Lassam N and Hogg D (1999) Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nature Genet 21: 128–132
MacKie RM, Andrew N, Lanyon WG and Connor JM (1998) CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 111: 269–272
Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, Cannon-Albright L, Bishop T, Kelsell D, Solomon E, Weber B, Couch F, Struewing J, Tonin P, Durocher F, Narod S, Skolnick MH, Lenoir G, Serova O, Ponder B, Stoppa-Lyonnet D, Easton D, King M-C and Goldgar DE (1996) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58: 271–280
Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King M-C, Ponder BAJ, Weber B, Devilee P, Borg A, Narod SA and Goldgar D (1998) Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 62: 1381–1388
Newton Bishop JA, Harland M, Bennett DC, Bataille V, Goldstein AM, Tucker MA, Ponder BAJ, Cuzick J, Selby P and Bishop DT (1999) Mutation testing in melanoma families: INK4A, CDK4, and INK4D. Br J Cancer 80: 295–300
Parry D and Peters G (1996) Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16: 3844–3852
Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J and Hayward NK (1998) Haplotype Analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mut 11: 424–431
Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C and DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713–723
Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, Serrano M, Hannon GJ, Beach D and Dracopoli NC (1995) Mutations associated with familial melanoma impair p16INK4 function. Nature Genet 10: 114–116
Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Newton Bishop J and Bishop DT (2001) A germline deletion of p14ARFbut not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Molec Genet 10: 55–62
Ruiz A, Puig S, Malvehy J, Lazaro C, Lynch M, Gimenez-Arnau AM, Puig L, Sanchez-Conejo J, Estivill X and Castel T (1999) CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanoma and other neoplasia. J Med Genet 36: 490–493
Serrano M, Hannon GJ and Beach D (1993) A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704–707
Serrano M, Gomez-Lahoz E, DePinho RA, Beach D and Bar-Sagi D (1995) Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 267: 249–252
Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, the French Familial Melanoma Study Group Benard J and Bressac-de Paillerets B (1998) Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 7: 209–216
Zhang Y, Xiong Y and Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92: 725–734
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Goldstein, A., Liu, L., Shennan, M. et al. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families. Br J Cancer 85, 527–530 (2001). https://doi.org/10.1054/bjoc.2001.1944
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1944
Keywords
This article is cited by
-
CDKN2A founder mutation in pancreatic ductal adenocarcinoma patients without cutaneous features of Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome
Hereditary Cancer in Clinical Practice (2018)
-
Germline splicing mutations of CDKN2A predispose to melanoma
Oncogene (2003)
-
Melanoma etiology: where are we?
Oncogene (2003)
-
Genetics of melanoma predisposition
Oncogene (2003)
